Friday, 27 March 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 27 March 2026
News

Now sports are looking at GLP-1s

Posted 27 March 2026 AM

Another regulatory body is looking at weight loss drugs, with the World Anti-Doping Agency (WADA) expanding its monitoring of the use of GLP-1 RAs to see if they are being abused by athletes and should be prohibited.

WADA began monitoring Novo Nordisk's semaglutide franchise, which includes Ozempic, Wegovy, and Rybelsus, both in and out of competition in 2024. The Monitoring Program for 2026 has seen Eli Lilly's tirzepatide franchise of Mounjaro and Zepbound added as well.

To see the whole article, please login

Popular

Company unveils role 'streamlining'
Why it's quitting time for pharma
Which pharmas are Most Ethical?
Pharma targets US$320B market
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home